Great f.y.i. Get hooked here!
Phase III study ARANOTE to be initiated in metastatic hormone-sensitive prostate cancer (mHSPC) assessing the androgen receptor inhibitor (ARi) in combination with standard androgen deprivation therapy (ADT) Start of patient enrollment expected by the end of Q1 2021 Study adds to the
• Metagenomi is a genomic medicines company pioneering precision gene editing systems to advance curative therapies for oncology and genetic diseases • Proprietary and wholly owned gene editing platform offers the potential to expand the range of treatable diseases and to improve patient
Data presented as a late-breaker during a virtual ALERT session at the annual meeting of the European Respiratory Society Outcomes from the randomized, controlled, open-label REPLACE study included results from 226 patients with pulmonary arterial hypertension (PAH) WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer today announced
WHIPPANY, N.J.–(BUSINESS WIRE)–Lori Moore, former Managing Director at Deloitte, will be joining Bayer as Vice President, Head of Pharmaceutical Communications in the United States, the company announced today. Moore spent the last six years in senior communications roles at Deloitte, most recently
• Bayer to reward growers to generate carbon credits by adopting climate-smart practices and creating a new revenue stream on-farm • The initiative makes Bayer the first company to develop a transparent, science-based and collaborative approach to a carbon market in agriculture
Company earns score of 90 and recognized as a Best Place to Work for Disability Inclusion WHIPPANY, N.J.–(BUSINESS WIRE)–For the second consecutive year, Bayer U.S. was recognized as a Best Place to Work for Disability Inclusion, earning a score of 90 in